| pubmed-article:21315272 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:21315272 | lifeskim:mentions | umls-concept:C0031809 | lld:lifeskim |
| pubmed-article:21315272 | lifeskim:mentions | umls-concept:C0005507 | lld:lifeskim |
| pubmed-article:21315272 | lifeskim:mentions | umls-concept:C0030956 | lld:lifeskim |
| pubmed-article:21315272 | lifeskim:mentions | umls-concept:C0205360 | lld:lifeskim |
| pubmed-article:21315272 | lifeskim:mentions | umls-concept:C1527240 | lld:lifeskim |
| pubmed-article:21315272 | lifeskim:mentions | umls-concept:C0348080 | lld:lifeskim |
| pubmed-article:21315272 | pubmed:issue | 2 | lld:pubmed |
| pubmed-article:21315272 | pubmed:dateCreated | 2011-2-14 | lld:pubmed |
| pubmed-article:21315272 | pubmed:abstractText | Lack of correlation between in vitro and in vivo stability is a general problem for the development of radiopeptides especially in the case of minigastrin derivatives for therapeutic applications. In this study, we compared the influence of experimental conditions on radiopeptide stability results in vitro using a model Minigastrin (MG) analogue labelled with Lu-177. Additionally, we attempted to characterize the main serum enzymatic cleavage sites by matrix-assisted laser desorption/ionization (MALDI) time-of-flight (TOF) mass spectrometry (MS) analysis. | lld:pubmed |
| pubmed-article:21315272 | pubmed:language | eng | lld:pubmed |
| pubmed-article:21315272 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21315272 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:21315272 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21315272 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21315272 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21315272 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21315272 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21315272 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21315272 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21315272 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21315272 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:21315272 | pubmed:month | Feb | lld:pubmed |
| pubmed-article:21315272 | pubmed:issn | 1872-9614 | lld:pubmed |
| pubmed-article:21315272 | pubmed:author | pubmed-author:OzsoyYY | lld:pubmed |
| pubmed-article:21315272 | pubmed:author | pubmed-author:KabasakalLeve... | lld:pubmed |
| pubmed-article:21315272 | pubmed:author | pubmed-author:DecristoforoC... | lld:pubmed |
| pubmed-article:21315272 | pubmed:author | pubmed-author:von... | lld:pubmed |
| pubmed-article:21315272 | pubmed:author | pubmed-author:KremserLeopol... | lld:pubmed |
| pubmed-article:21315272 | pubmed:author | pubmed-author:HelbokAnnaA | lld:pubmed |
| pubmed-article:21315272 | pubmed:author | pubmed-author:OcakMeltemM | lld:pubmed |
| pubmed-article:21315272 | pubmed:copyrightInfo | Copyright © 2011 Elsevier Inc. All rights reserved. | lld:pubmed |
| pubmed-article:21315272 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:21315272 | pubmed:volume | 38 | lld:pubmed |
| pubmed-article:21315272 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:21315272 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:21315272 | pubmed:pagination | 171-9 | lld:pubmed |
| pubmed-article:21315272 | pubmed:meshHeading | pubmed-meshheading:21315272... | lld:pubmed |
| pubmed-article:21315272 | pubmed:meshHeading | pubmed-meshheading:21315272... | lld:pubmed |
| pubmed-article:21315272 | pubmed:meshHeading | pubmed-meshheading:21315272... | lld:pubmed |
| pubmed-article:21315272 | pubmed:meshHeading | pubmed-meshheading:21315272... | lld:pubmed |
| pubmed-article:21315272 | pubmed:meshHeading | pubmed-meshheading:21315272... | lld:pubmed |
| pubmed-article:21315272 | pubmed:meshHeading | pubmed-meshheading:21315272... | lld:pubmed |
| pubmed-article:21315272 | pubmed:meshHeading | pubmed-meshheading:21315272... | lld:pubmed |
| pubmed-article:21315272 | pubmed:meshHeading | pubmed-meshheading:21315272... | lld:pubmed |
| pubmed-article:21315272 | pubmed:meshHeading | pubmed-meshheading:21315272... | lld:pubmed |
| pubmed-article:21315272 | pubmed:meshHeading | pubmed-meshheading:21315272... | lld:pubmed |
| pubmed-article:21315272 | pubmed:meshHeading | pubmed-meshheading:21315272... | lld:pubmed |
| pubmed-article:21315272 | pubmed:meshHeading | pubmed-meshheading:21315272... | lld:pubmed |
| pubmed-article:21315272 | pubmed:meshHeading | pubmed-meshheading:21315272... | lld:pubmed |
| pubmed-article:21315272 | pubmed:meshHeading | pubmed-meshheading:21315272... | lld:pubmed |
| pubmed-article:21315272 | pubmed:meshHeading | pubmed-meshheading:21315272... | lld:pubmed |
| pubmed-article:21315272 | pubmed:meshHeading | pubmed-meshheading:21315272... | lld:pubmed |
| pubmed-article:21315272 | pubmed:meshHeading | pubmed-meshheading:21315272... | lld:pubmed |
| pubmed-article:21315272 | pubmed:meshHeading | pubmed-meshheading:21315272... | lld:pubmed |
| pubmed-article:21315272 | pubmed:meshHeading | pubmed-meshheading:21315272... | lld:pubmed |
| pubmed-article:21315272 | pubmed:meshHeading | pubmed-meshheading:21315272... | lld:pubmed |
| pubmed-article:21315272 | pubmed:year | 2011 | lld:pubmed |
| pubmed-article:21315272 | pubmed:articleTitle | Influence of biological assay conditions on stability assessment of radiometal-labelled peptides exemplified using a 177Lu-DOTA-minigastrin derivative. | lld:pubmed |
| pubmed-article:21315272 | pubmed:affiliation | Clinical Department of Nuclear Medicine, Medical University Innsbruck, A-6020, Innsbruck, Austria. | lld:pubmed |
| pubmed-article:21315272 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:21315272 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
